Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Heron Therapeutics, Inc. (the "Company") issued a press release announcing, among other things, certain of its preliminary financial results for the three and twelve months ended December 31, 2022 (the "Press Release"). A copy of the Press Release is furnished herewith as Exhibit 99.1.

This Item 2.02 and the Press Release attached hereto as Exhibit 99.1 are being furnished to the Securities and Exchange Commission.

Item 7.01 Regulation FD Disclosure.

On January 9, 2023, the Company issued the Press Release providing, among other things, a general update on corporate progress and preliminary financial results, as described in the Press Release.

This Item 7.01 and the Press Release attached hereto as Exhibit 99.1 are being furnished to the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit No.   Description

99.1            Press Release, dated January 9, 2023
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses